Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
30.07
USD
|
+2.59%
|
|
+2.28%
|
+3.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,244
|
1,326
|
1,551
|
1,928
|
1,581
|
1,646
|
-
|
-
|
Enterprise Value (EV)
1 |
1,262
|
1,326
|
1,551
|
1,928
|
1,581
|
1,646
|
1,646
|
1,646
|
P/E ratio
|
11.3
x
|
10.7
x
|
29.8
x
|
34.3
x
|
1,447
x
|
-3,007
x
|
-69.9
x
|
29.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.17
x
|
2.55
x
|
2.67
x
|
2.89
x
|
2.6
x
|
2.74
x
|
2.68
x
|
2.37
x
|
EV / Revenue
|
3.17
x
|
2.55
x
|
2.67
x
|
2.89
x
|
2.6
x
|
2.74
x
|
2.68
x
|
2.37
x
|
EV / EBITDA
|
-
|
6.91
x
|
13.1
x
|
15
x
|
16.2
x
|
18
x
|
15.3
x
|
9.81
x
|
EV / FCF
|
8.86
x
|
9.82
x
|
12.4
x
|
16.6
x
|
-
|
18.8
x
|
14.8
x
|
10.1
x
|
FCF Yield
|
11.3%
|
10.2%
|
8.07%
|
6.04%
|
-
|
5.33%
|
6.77%
|
9.87%
|
Price to Book
|
2.09
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
52,463
|
52,685
|
53,181
|
54,058
|
54,633
|
54,735
|
-
|
-
|
Reference price
2 |
23.72
|
25.16
|
29.16
|
35.67
|
28.94
|
30.07
|
30.07
|
30.07
|
Announcement Date
|
25/02/20
|
25/02/21
|
13/04/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
392.8
|
520.4
|
579.8
|
667.2
|
607.5
|
601.5
|
614.7
|
693.4
|
EBITDA
1 |
-
|
191.8
|
118.6
|
128.8
|
97.3
|
91.43
|
107.5
|
167.8
|
EBIT
1 |
148.6
|
173.7
|
86.03
|
46.12
|
125.1
|
106.3
|
113.9
|
175
|
Operating Margin
|
37.83%
|
33.38%
|
14.84%
|
6.91%
|
20.59%
|
17.68%
|
18.52%
|
25.23%
|
Earnings before Tax (EBT)
1 |
147.5
|
168.6
|
73.18
|
60.74
|
2.769
|
5.857
|
-19.91
|
47.56
|
Net income
1 |
113.1
|
127
|
53.42
|
60.71
|
1.316
|
7.234
|
-24.59
|
58.74
|
Net margin
|
28.79%
|
24.39%
|
9.21%
|
9.1%
|
0.22%
|
1.2%
|
-4%
|
8.47%
|
EPS
2 |
2.100
|
2.360
|
0.9800
|
1.040
|
0.0200
|
-0.0100
|
-0.4300
|
1.030
|
Free Cash Flow
1 |
140.4
|
135
|
125.1
|
116.4
|
-
|
87.7
|
111.4
|
162.4
|
FCF margin
|
35.75%
|
25.93%
|
21.57%
|
17.45%
|
-
|
14.58%
|
18.12%
|
23.42%
|
FCF Conversion (EBITDA)
|
-
|
70.35%
|
105.44%
|
90.42%
|
-
|
95.92%
|
103.58%
|
96.79%
|
FCF Conversion (Net income)
|
124.18%
|
106.3%
|
234.13%
|
191.75%
|
-
|
1,212.33%
|
-
|
276.49%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
25/02/21
|
13/04/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
148.5
|
159
|
152.5
|
170.1
|
177.4
|
167.3
|
153.8
|
135.6
|
153.9
|
164.3
|
145.8
|
148.8
|
154.3
|
152.5
|
152.6
|
EBITDA
1 |
-
|
-
|
22.61
|
31.99
|
19.12
|
55.03
|
25.14
|
2.521
|
29.38
|
40.26
|
13.77
|
17.69
|
26.47
|
16.93
|
-
|
EBIT
1 |
32.6
|
6.098
|
1.967
|
11.35
|
-1.523
|
34.33
|
30.5
|
10
|
8.138
|
47.1
|
22.92
|
24.2
|
29.44
|
29.78
|
34.5
|
Operating Margin
|
21.96%
|
3.83%
|
1.29%
|
6.67%
|
-0.86%
|
20.52%
|
19.84%
|
7.38%
|
5.29%
|
28.66%
|
15.71%
|
16.26%
|
19.08%
|
19.53%
|
22.61%
|
Earnings before Tax (EBT)
1 |
28.96
|
2.051
|
14.72
|
11.32
|
-0.444
|
35.14
|
9.017
|
-17.13
|
9.889
|
0.99
|
-3.483
|
0.44
|
9.216
|
-0.316
|
-
|
Net income
1 |
21.56
|
2.442
|
25.62
|
7.865
|
1.749
|
25.48
|
16.95
|
-0.831
|
-15.98
|
1.175
|
-4.301
|
0.543
|
11.38
|
-0.39
|
-
|
Net margin
|
14.52%
|
1.54%
|
16.8%
|
4.63%
|
0.99%
|
15.23%
|
11.02%
|
-0.61%
|
-10.38%
|
0.72%
|
-2.95%
|
0.36%
|
7.38%
|
-0.26%
|
-
|
EPS
2 |
0.4000
|
0.0400
|
0.4300
|
0.1400
|
0.0300
|
0.4300
|
0.2900
|
-0.0200
|
-0.2900
|
0.0200
|
-0.0800
|
0.0100
|
0.2000
|
-0.0100
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/11/21
|
13/04/22
|
09/05/22
|
04/08/22
|
08/11/22
|
28/02/23
|
09/05/23
|
08/08/23
|
08/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
17.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
140
|
135
|
125
|
116
|
-
|
87.7
|
111
|
162
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
11.30
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
2.660
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.74
|
3.45
|
2.05
|
0.41
|
-
|
4
|
4.25
|
7
|
Capex / Sales
|
0.7%
|
0.66%
|
0.35%
|
0.06%
|
-
|
0.67%
|
0.69%
|
1.01%
|
Announcement Date
|
25/02/20
|
25/02/21
|
13/04/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
30.07
USD Average target price
40.33
USD Spread / Average Target +34.13% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.90% | 1.65B | | +5.31% | 70.44B | | +10.97% | 8.94B | | -16.83% | 4.75B | | +43.48% | 4.5B | | +3.20% | 3.85B | | -21.36% | 2.34B | | -29.67% | 2.2B | | +8.38% | 1.96B | | -0.50% | 1.64B |
Specialty & Advanced Pharmaceuticals
|